When model mice with GBM and melanoma overexpressed VEGF-C, the anti-PD-1/CTLA-4 combination treatment showed a good effect, which was abolished when CCL21/CCR7 blockaded, suggesting an augmented effect of VEGF-C on checkpoint treatment via the CCL21/CCR7 pathway (100). The gene discussed is CCL21; the disease is glioblastoma.